Conference Coverage

Beware nonopiate meds with high street value


 

EXPERT ANALYSIS FROM ACP INTERNAL MEDICINE


Overdoses involving gabapentinoids alone are uncommon because they require consumption at up to 25 times the maximum recommended dose. Moreover, these overdoses are rarely fatal.

“You almost can’t overdose on a gabapentinoid, because you have to take lots and lots of it to do so, and you’ll usually survive. But if you add it to an opioid or other sedative, then you’re really in dangerous territory. That’s where all the deaths are clustered,” Dr. Walley explained.

A recent Canadian/Dutch population-based, nested, case-control study concluded that concomitant prescription of opioids and gabapentin was associated with a 49% greater chance of fatal overdose, compared with opioid prescription alone, in an analysis extensively adjusted for potential confounders. A dose-response effect was noted, such that coprescription of high-dose gabapentin was linked to an adjusted 58% increased risk (PLoS Med. 2017 Oct 3;14[10]:e1002396).

Complicating the picture, however, is solid evidence from a randomized, placebo-controlled, crossover trial that gabapentin and opioids are synergistic for relief from neuropathic pain, which can be notoriously difficult to control (N Engl J Med. 2005 Mar 31;352[13]:1324-34).

Pages

Recommended Reading

MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Rheumatology
CMS finalizes measures to help combat opioid crisis
MDedge Rheumatology
Life and health are not even across the U.S.
MDedge Rheumatology
Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Rheumatology
Mixed outcomes in analysis of NSAIDs and IBD exacerbation
MDedge Rheumatology
MDedge Daily News: Shingles boosts stroke risk
MDedge Rheumatology
MDedge Daily News: Can a nasal spray reverse suicidality?
MDedge Rheumatology
MDedge Daily News: Physician burnout needs more than yoga
MDedge Rheumatology
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Rheumatology
FDA advisory committee votes to recommend update to celecoxib safety labeling
MDedge Rheumatology